Drug Profile
Research programme: human papillomavirus infections therapeutics - NanoVir
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator NanoVir
- Class Antivirals
- Mechanism of Action DNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Human papillomavirus infections
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Human-papillomavirus-infections in USA (Topical)
- 19 Jul 2016 Preclinical development is ongoing in USA